FDA Accepts Priority Review NDA for Potential Niemann-Pick Disease Type C Drug
source: pixabay.com

FDA Accepts Priority Review NDA for Potential Niemann-Pick Disease Type C Drug

According to a story from globenewswire.com, the US Food and Drug Administration (FDA) recently accepted the New Drug Application (NDA) for arimoclomol. This application is for the use of the…

Continue Reading FDA Accepts Priority Review NDA for Potential Niemann-Pick Disease Type C Drug
Enrollment for Phase 2 Amyotrophic Lateral Sclerosis Trial is Complete
source: pixabay.com

Enrollment for Phase 2 Amyotrophic Lateral Sclerosis Trial is Complete

According to a story from BioSpace, the biopharmaceutical company Clene Nanomedicine, Inc., has recently announced that it has completed the process of enrollment patient participants in its upcoming phase 2…

Continue Reading Enrollment for Phase 2 Amyotrophic Lateral Sclerosis Trial is Complete

Researchers at Nagoya University are One Step Closer to Unraveling the Tau Mystery in Neurodegenerative Diseases

According to a recent article in MedicalXpress, researchers in Japan led by Dr. Shinsuke Ishigaki and his team at Nagoya University, have identified new molecular details about tau’s activity. Alzheimer’s,…

Continue Reading Researchers at Nagoya University are One Step Closer to Unraveling the Tau Mystery in Neurodegenerative Diseases
Preclinical Data Supports NurOwn for ALS, MS, and Alzheimer’s Disease
Source: Pixabay

Preclinical Data Supports NurOwn for ALS, MS, and Alzheimer’s Disease

  Within the last month, BrainStorm Cell Therapeutics Inc. announced the publication of pre-clinical data on the NurOwn system. NurOwn technology produces autologous, bone marrow-derived mesenchymal stem cells (MSCs) for…

Continue Reading Preclinical Data Supports NurOwn for ALS, MS, and Alzheimer’s Disease

Editor’s Choice: Experimental Trial for ALS and New Insights on COVID-19

Happy Friday! We're about halfway through Stevens-Johnson Syndrome Awareness Month. It's a type of severe skin reaction that often involves admission to a burn unit for treatment. Looking for ways…

Continue Reading Editor’s Choice: Experimental Trial for ALS and New Insights on COVID-19
Study: Verdiperstat as a Treatment for Amyotrophic Lateral Sclerosis (ALS)
source: pixabay.com

Study: Verdiperstat as a Treatment for Amyotrophic Lateral Sclerosis (ALS)

The HEALY ALS Platform Trial, being conducted by Biohaven Pharma, has begun enrolling patients. This study is intended to test the efficacy of three treatments on amyotrophic lateral sclerosis (ALS),…

Continue Reading Study: Verdiperstat as a Treatment for Amyotrophic Lateral Sclerosis (ALS)
Scientists Can Identify Schwann Cells Using Novel Bar Code Technique
Image by Markus Spiske from Pixabay

Scientists Can Identify Schwann Cells Using Novel Bar Code Technique

Scientists and researchers have long known how important glial cells are to the nervous system. Not only do these cells make up a majority of cells within the central nervous…

Continue Reading Scientists Can Identify Schwann Cells Using Novel Bar Code Technique
New Drug Application for Niemann-Pick Disease Type C Treatment Submitted Under Rolling Review
source: pixabay.com

New Drug Application for Niemann-Pick Disease Type C Treatment Submitted Under Rolling Review

According to a story from globenewswire.com, the biopharmaceutical company Orphazyme A/S has recently announced that it has submitted its New Drug Application (NDA) for its experimental treatment arimoclomol to the…

Continue Reading New Drug Application for Niemann-Pick Disease Type C Treatment Submitted Under Rolling Review
Arimoclomol Receives the Fast Track Designation for the Treatment of ALS
source: pixabay.com

Arimoclomol Receives the Fast Track Designation for the Treatment of ALS

CytRx Corporation has recently received the Fast Track designation for their ALS treatment, arimoclomol. This status was also given for the treatment of Niemann-Pick disease and sporadic Inclusion Body Myositis…

Continue Reading Arimoclomol Receives the Fast Track Designation for the Treatment of ALS
Exploring the Similar Pathology “Genetic Doppelgängers” ALS and SCA36
Thor_Deichmann / Pixabay

Exploring the Similar Pathology “Genetic Doppelgängers” ALS and SCA36

Recently, scientists from Emory University set out to discover whether there was any pathological link between spinocerebellar ataxia type 36 (SCA36) and amyotrophic lateral sclerosis and frontotemporal dementia (ALS/FTD). Both…

Continue Reading Exploring the Similar Pathology “Genetic Doppelgängers” ALS and SCA36
Could Biobots be the Key to Understanding ALS and other Neuromuscular Diseases?
source: pixabay.com

Could Biobots be the Key to Understanding ALS and other Neuromuscular Diseases?

  Biological robots, commonly known as biobots, mimic the actions of other organisms (e.g. jumping or swimming). Biobots are composed of artificial materials and also organic material. As published in…

Continue Reading Could Biobots be the Key to Understanding ALS and other Neuromuscular Diseases?
New Therapy for ALS and Other Neurodegenerative Diseases
geralt / Pixabay

New Therapy for ALS and Other Neurodegenerative Diseases

ProMIS Neurosciences is a biotechnology company that works specifically with antibody treatments, and they have recently developed intrabodies for the treatment of amyotrophic lateral sclerosis (ALS). This same therapy has…

Continue Reading New Therapy for ALS and Other Neurodegenerative Diseases

Seneca Biopharma Preparing for its Phase 3 Trial to Test NSI-566 for Amyotrophic Lateral Sclerosis

Seneca Biopharma, Germantown, Md., issued a press release announcing its recent meeting with the FDA to discuss elements of a final design and protocol for a Phase 3 trial investigating…

Continue Reading Seneca Biopharma Preparing for its Phase 3 Trial to Test NSI-566 for Amyotrophic Lateral Sclerosis
How Do Ventilators Work?: A Video Review During COVID-19
source: pixabay.com

How Do Ventilators Work?: A Video Review During COVID-19

  If you have read the news at all lately, you know that ventilators are a sought-after piece of medical equipment. With hospitals looking to treat mass amounts of patients…

Continue Reading How Do Ventilators Work?: A Video Review During COVID-19
Researchers Discover New Gene that Contributes to the Progression of ALS
source: pixabay.com

Researchers Discover New Gene that Contributes to the Progression of ALS

Researchers at Columbia University have discovered a new gene, TBK1, that is linked to the progression of amyotrophic lateral sclerosis (ALS). A lack of understanding of a rare disease hinders…

Continue Reading Researchers Discover New Gene that Contributes to the Progression of ALS

Study Highlights Need to Support Youth Acting as Amyotrophic Lateral Sclerosis Caregivers

A recent study, conducted my Melinda Kavanaugh from the University of Wisconsin, Milwaukee, examined the role of children who are acting as caregivers for those diagnosed with amyotrophic lateral sclerosis…

Continue Reading Study Highlights Need to Support Youth Acting as Amyotrophic Lateral Sclerosis Caregivers
Neurodegenerative-Neuromuscular Diseases and Airway Clearance Therapy
source: pixabay.com

Neurodegenerative-Neuromuscular Diseases and Airway Clearance Therapy

  Advances in medicine have been responsible for longer overall survival in patients with neurodegenerative-neuromuscular diseases. According to a recent report in RTMagazine, an increase in the number of patients…

Continue Reading Neurodegenerative-Neuromuscular Diseases and Airway Clearance Therapy

ICYMI: The FDA Grants Orphan Status to a New Combination Drug to Treat ALS 

  According to a recent article in ALS News Today, the FDA’s Orphan Status designation has been granted to NeuroSense Therapeutics for its drug, PrimeC, to treat ALS. PrimeC received the designation…

Continue Reading ICYMI: The FDA Grants Orphan Status to a New Combination Drug to Treat ALS 
Orphan Drug Designation and Two New Clinical Trials for ALS Treatment
source: pixabay.com

Orphan Drug Designation and Two New Clinical Trials for ALS Treatment

NeuroSense Therapeutics, a biotechnology company, is in the process of developing PrimeC. PrimeC was created for the treatment of amyotrophic lateral sclerosis (ALS), and it is meant to slow or…

Continue Reading Orphan Drug Designation and Two New Clinical Trials for ALS Treatment
Close Menu